Jun 20Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Mar 30ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Aug 9, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Mar 15, 2022Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Aug 12, 2021Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
